In the past week, BCLI stock has gone down by -9.92%, with a monthly gain of 0.93% and a quarterly plunge of -22.14%. The volatility ratio for the week is 8.00%, and the volatility levels for the last 30 days are 8.41% for Brainstorm Cell Therapeutics, Inc The simple moving average for the past 20 days is -7.08% for BCLI’s stock, with a -38.14% simple moving average for the past 200 days.
Is It Worth Investing in Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) Right Now?
The 36-month beta value for BCLI is also noteworthy at 0.22. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BCLI is 6.17M, and at present, short sellers hold a 7.51% of that float. The average trading volume of BCLI on June 27, 2025 was 1.33M shares.
BCLI) stock’s latest price update
Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) has experienced a decline in its stock price by -7.63 compared to its previous closing price of 1.18. However, the company has seen a fall of -9.92% in its stock price over the last five trading days. prnewswire.com reported 2025-06-16 that NEW YORK, June 16, 2025 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data from 10 participants in its Expanded Access Program (EAP) for NurOwn® (autologous MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The EAP enrolled 10 participants who had previously completed the Phase 3 clinical trial.
Analysts’ Opinion of BCLI
Many brokerage firms have already submitted their reports for BCLI stocks, with Maxim Group repeating the rating for BCLI by listing it as a “Buy.” The predicted price for BCLI in the upcoming period, according to Maxim Group is $12 based on the research report published on February 04, 2021 of the previous year 2021.
Maxim Group gave a rating of “Buy” to BCLI, setting the target price at $6 in the report published on December 19th of the previous year.
BCLI Trading at -3.68% from the 50-Day Moving Average
After a stumble in the market that brought BCLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.48% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCLI starting from Lebovits Chaim, who purchase 1,836 shares at the price of $3.43 back on Oct 01 ’24. After this action, Lebovits Chaim now owns 80,960 shares of Brainstorm Cell Therapeutics, Inc, valued at $6,292 using the latest closing price.
Lebovits Chaim, the President & CEO of Brainstorm Cell Therapeutics, Inc, purchase 22,000 shares at $0.23 during a trade that took place back on Sep 30 ’24, which means that Lebovits Chaim is holding 1,186,865 shares at $5,016 based on the most recent closing price.
Stock Fundamentals for BCLI
The total capital return value is set at 1.68.
Based on Brainstorm Cell Therapeutics, Inc (BCLI), the company’s capital structure generated -0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -4.33.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.21.
Conclusion
In summary, Brainstorm Cell Therapeutics, Inc (BCLI) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
